Publicacións nas que colabora con SANTIAGO RODRIGUEZ-SEGADE VILLAMARIN (29)

2023

  1. Prevalence and Risk Factors for Airflow Limitation in Patients With Acute Coronary Syndrome

    Archivos de Bronconeumologia, Vol. 59, Núm. 6, pp. 397-400

2022

  1. At-admission HbA1c levels in hospitalized COVID-19 participants with and without known diabetes

    Clinica Chimica Acta, Vol. 532, pp. 188-192

  2. The oxyhaemoglobin dissociation curve is generally left-shifted in COVID-19 patients at admission to hospital, and this is associated with lower mortality

    British Journal of Haematology, Vol. 199, Núm. 3, pp. 332-338

2019

  1. Prediabetes defined by HbA1c and by fasting glucose: differences in risk factors and prevalence

    Acta Diabetologica, Vol. 56, Núm. 9, pp. 1023-1030

2018

  1. Continuous glucose monitoring is more sensitive than HbA1c and fasting glucose in detecting dysglycaemia in a Spanish population without diabetes

    Diabetes Research and Clinical Practice, Vol. 142, pp. 100-109

2017

  1. Corrected Fructosamine improves both correlation with HbA1C and diagnostic performance

    Clinical Biochemistry, Vol. 50, Núm. 3, pp. 110-115

2016

  1. Impact of mean cell hemoglobin on Hb A1c-defined glycemia status

    Clinical Chemistry, Vol. 62, Núm. 12, pp. 1570-1578

2015

  1. Influence of the glycation gap on the diagnosis of type 2 diabetes

    Acta Diabetologica, Vol. 52, Núm. 3, pp. 453-459

2012

  1. Estimation of the glycation gap in diabetic patients with stable glycemic control

    Diabetes Care, Vol. 35, Núm. 12, pp. 2447-2450

  2. Intrapersonal HbA1c variability and the risk of progression of nephropathy in patients with Type2 diabetes

    Diabetic Medicine, Vol. 29, Núm. 12, pp. 1562-1566

2011

  1. Progression of nephropathy in type 2 diabetes: The glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A1c)

    Clinical Chemistry, Vol. 57, Núm. 2, pp. 264-271

2009

  1. Actualización en el laboratorio clínico, 2009

    Departamento de Bioquímica e Bioloxía Molecular

  2. Translating the A1C assay into estimated average glucose values

    Diabetes Care

2008

  1. Actualización en el laboratorio clínico, 2008

    Departamento de Bioquímica e Bioloxía Molecular

2007

  1. Tissue-polypeptide-specific antigen levels in diabetic patients with normal and pathological biochemical profiles

    Clinical Biochemistry, Vol. 40, Núm. 3-4, pp. 278-281

2006

  1. Treatment of Mitochondrial Encephalomyopathies With a Xanthine Oxidase Inhibitor

    Pediatric Neurology, Vol. 35, Núm. 5, pp. 318-322

2005

  1. Plasma albumin concentration is a predictor of HbA1c among type 2 diabetic patients, independently of fasting plasma glucose and fructosamine

    Diabetes Care, Vol. 28, Núm. 2, pp. 437-439

2003

  1. Neuron-specific enolase, nucleotides, nucleosides, purine bases, oxypurines and uric acid concentrations in cerebrospinal fluid of children with meningitis

    Brain and Development, Vol. 25, Núm. 2, pp. 102-106

2001

  1. Concentrations of nucleotides, nucleosides, purine bases, oxypurines, uric acid, and neuron-specific enolase in the cerebrospinal fluid of children with sepsis

    Journal of Child Neurology, Vol. 16, Núm. 9, pp. 704-706

2000

  1. Cerebrospinal fluid purine metabolite and neuron-specific enolase concentrations after febrile seizures

    Brain and Development, Vol. 22, Núm. 7, pp. 427-431